 |
|
|
 |
|
Rationale:
- Because no chemoprophylactic regimen is 100% effective, measures should be taken to reduce vector exposure.
|
|
Evidence:
- Of 799 patients with imported malaria with onset of illness in 2002 and for whom prophylaxis information was available, 21%
took a CDC-recommended drug for the area of travel, indicating that chemoprophylaxis regimens are not 100% effective and that
measures should be taken to reduce mosquito exposure as well (22).
- One questionnaire-based survey of 89,617 European tourists returning from East Africa found that the incidence of malaria
was significantly reduced by sleeping in an air-conditioned room (P=0.04) and wearing long-sleeved shirts and trousers (P=0.02) (31).
- A systematic review of 18 randomized, controlled trials in malaria-endemic settings (involving nontravelers) found that nets
impregnated or sprayed with permethrin reduced the number of mild malaria episodes (absolute risk reduction 39%; 27% to 48%)
and child mortality (relative risk of death, 0.83; 0.77 to 0.90) compared with no nets or untreated nets (32).
- A community-based, randomized, controlled trial in an area of intense perennial transmission in western Kenya showed that
permethrin-treated bed nets reduced P. falciparum transmission by 90%. Bed net efficacy (as measured by percent reduction in Anopheles gambiae feeding) declined with increasing number of days since previous insecticide application, as follows: <90 days, 82%; 90 to
180 days, 63%; >180 days, 17% (33).
- A case-control study (96 cases, 613 controls) showed that the use of insect repellant soap (containing 20% DEET, 0.5% permethrin)
reduced the risk of malaria by 92% in an Afghan population also using insecticide-treated bed nets (adjusted OR, 0.08 [CI,
0.01 to 0.61]; P=0.001) (34).
- A cluster-randomized, placebo-controlled trial involving 127 Afghan refugee families showed that the use of insect repellant
soap (containing 20% DEET, 0.5% permethrin) reduced the risk of P. falciparum malaria by 56% over 6 months of follow-up (OR, 0.44 [CI, 0.25 to 0.76]; P=0.004) (35).
- A small nonrandomized, controlled trial in eight U.S. Air Force recruits found that permethrin-treated uniforms significantly
reduced the risk of mosquito bites over 8 hours (relative risk reduction, 93% [P<0.01]). The topical application of DEET further reduced the risk of mosquito bites (relative risk reduction, 99.9% [P<0.01]) (36).
- Although one study did not associate the use of a commercially available insecticide with malaria protection (P>0.2) (31); one randomized, controlled trial involving eight people showed that insect repellent soap (20% DEET, 0.5% permethrin) reduced
the number of sand fly bites for up to 8 hours (P<0.05) (37).
|
|
Comments:
- Travelers taking chemoprophylaxis frequently have a false sense of security, leading them to ignore mosquito repellent measures.
A survey of North American and European travelers returning from Africa found that although 95% used chemoprophylaxis, only
62% used both chemoprophylaxis and two or more antimosquito measures (38).
- Products containing ~30% DEET are considered safe and effective for 4 to 6 hours in adults and children older than 2 months,
if used according to the manufacturer's directions. A useful list of products and manufacturer contact information has been
compiled (39). Instructions on the appropriate application of DEET products are provided by the EPA.
- Products containing niacin, citronella, and other plant and animal oils provide little if any protection. Some perfumed products
may attract mosquitoes.
- Bed nets should be treated with permethrin (300 to 500 mg/m2) every 6 months to maintain effectiveness (40). Permethrin-treated clothing and nets are safe for pregnant women and children. Bed nets should be properly tucked under
the mattress to prevent access by mosquitoes.
|
| FAQs |
|
|
|
Harry Tagbor, MBChB, DrPH, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Rick M. Fairhurst, MD, PhD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Thomas E. Wellems, MD, PhD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for
continuing medical education grand rounds and lectures given.
|
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|